TARA
Protara Therapeutics Inc.
| Dec 2014 | |
|---|---|
| Revenue | |
| Revenue | 2.9M |
| Cost of Revenue | — |
| Gross Profit | — |
| Operating Expenses | |
| R&D Expenses | — |
| SG&A Expense | — |
| Total Op. Expenses | — |
| Operating Income | -7.6M |
| EBITDA | — |
| Below the Line | |
| Interest Expense | — |
| Pre-Tax Income | — |
| Income Tax | — |
| Net Income | -3.3M |
| Per Share | |
| EPS (basic) | — |
| EPS (diluted) | — |
| Shares | |
| Basic Shares | — |
| Diluted Shares | 16M |